Cookie policy: This site uses cookies (small files stored on your computer) to simplify and improve your experience of this website. Cookies are small text files stored on the device you are using to access this website. For more information please take a look at our terms and conditions. Some parts of the site may not work properly if you choose not to accept cookies.

Your RPS

MEP 43 out now

MEP 43 will be distributed to UK-based members of the Royal Pharmaceutical Society with the July 2019 issue of The Pharmaceutical Journal.

MEP 43

Source: Royal Pharmaceutical Society

The 43rd edition of Medicines, Ethics and Practice includes guidance on the sale and supply of medical cannabis

Guidance on the sale and supply of medical cannabis and cannabidiol (CBD) oils is one of several new additions to the 43rd edition of Medicines, Ethics and Practice (MEP), a professional guide for pharmacists which has been published by the Royal Pharmaceutics Society (RPS).

A new section on cannabis-based products summarises the difference between CBD oils, licensed cannabis-derived and synthetic products and cannabis-based products for medicinal use (CBPMs). It also provides advice on supplying CPBMs for a prescription and signposts to guidance from bodies including the RPS, the Medicines and Healthcare products Regulatory Agency and the Home Office. 

Sonia Garner, professional standards adviser at the RPS, said: “We know from media coverage and discussions with key stakeholders that there needs to be some key information about these products readily available for pharmacists.

“We worked with the Department of Health and Social Care and Guy’s and St Thomas’ NHS Foundation Trust and the MEP advisory panel to include this [section] in MEP

“We have also added a section on prescriptions from the Crown dependencies — Jersey, Guernsey and the Isle of Man — which was introduced following a discussion by the MEP advisory panel.” 

Among other updates, the chapter on medicines optimisation and pharmaceutical care now signposts to the RPS’s guidance on ‘Polypharmacy: Getting our medicines right’, and the chapter on controlled drugs includes a summary of responses to the Gosport Independent Panel’s report. There is also a brief summary of the Falsified Medicines Directive (FMD), with a pointer to the Society’s online FMD Hub.  

Other changes include adding gabapentin and pregabalin to the section on prescription requirements for controlled drugs, and renaming and updating the section on contining professional development to include revalidation requirements.  

The 43rd edition of MEP, MEP 43, will be distributed to UK-based members with the July 2019 issue of The Pharmaceutical Journal. Printed copies of MEP 43 are not sent to overseas members, or students and retired members, but an online version is available for members to download from the RPS website.

The RPS is keen to hear from members interested in joining the MEP advisory panel for future updates. Volunteers from across Great Britain, at all career stages and from any sector, who are interested in joining are asked to get in touch at support@rpharms.com

Citation: The Pharmaceutical Journal DOI: 10.1211/PJ.2019.20206824

Have your say

For commenting, please login or register as a user and agree to our Community Guidelines. You will be re-directed back to this page where you will have the ability to comment.

Recommended from Pharmaceutical Press

Search an extensive range of the world’s most trusted resources

Powered by MedicinesComplete
PJJ Static MPU
  • Print
  • Share
  • Comment
  • Save
  • Print Friendly Version of this pagePrint Get a PDF version of this webpagePDF

Jobs you might like

Newsletter Sign-up

Want to keep up with the latest news, comment and CPD articles in pharmacy and science? Subscribe to our free alerts.